Rapport Therapeutics (RAPP) Conference Summary Company Overview - Company: Rapport Therapeutics - CEO: Abe Sisan, with over 20 years in the biotech sector, previously president of Cerevel Therapeutics [doc id='4'][doc id='5'] - CFO: Troy Nelzi, with extensive experience in finance and business development, raised approximately $5 billion for eight approved products [doc id='3'] Industry Focus - Sector: Biotech, specifically in neuroscience and anti-seizure medications - Key Product: RAP two one nine (RAP-219), a TARP gamma eight AMPA modulator targeting focal epilepsy [doc id='7'][doc id='10'] Core Scientific Insights - Receptor Associated Proteins (RAPs): Critical for regulating receptor function and signal transduction, allowing for targeted modulation of AMPA receptors [doc id='6'][doc id='8'] - Differentiation: RAP-219 aims to achieve significant seizure suppression without common adverse effects like sedation or motor impairment, presenting a potentially unprecedented therapeutic index [doc id='10][doc id='11'] Clinical Development - Preclinical Evidence: High probability of success in translating preclinical findings to clinical efficacy in epilepsy, with RAP-219 showing significant efficacy across various models [doc id='12'] - Phase 2a Trial: Utilizing an RNS device for objective measurement of efficacy, focusing on long episodes as a biomarker for seizure activity [doc id='15][doc id='16'] - Expected Outcomes: Aiming for a 30% reduction in long episodes correlating with at least a 50% reduction in clinical seizures, with results expected in Q3 2025 [doc id='31][doc id='34] Community Engagement and Feedback - Interest from KOLs: Significant interest in the trial design and methodology, viewed as a step forward in drug development for epilepsy [doc id='26][doc id='27'] - Data Presentation: Recent presentations at the American Academy of Neurology meeting highlighted the predictive value of long episode reductions for clinical seizure outcomes [doc id='28][doc id='29] Future Directions - Next Steps: If data is positive, plans to move into parallel Phase 2b/3 registrational trials [doc id='35] - Pipeline Expansion: Plans to initiate studies for bipolar mania and neuropathic pain, with data expected in early 2027 for bipolar mania [doc id='40] Conclusion - Rapport Therapeutics is positioned to potentially transform the treatment landscape for epilepsy and other neurological conditions through its innovative approach to drug development and its focus on precision neuroscience [doc id='39]
Rapport Therapeutics (RAPP) Conference Transcript